Overview

Brequinar Combined With Dipyridamole in Patients With Mild to Moderate SARS-CoV-2 Infection.

Status:
Not yet recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
A Phase 2 multi-center, assessor-blind, randomized study to assess the safety, tolerability, and antiviral activity of brequinar in combination with dipyridamole.
Phase:
Phase 2
Details
Lead Sponsor:
Clear Creek Bio, Inc.
Treatments:
Brequinar
Dipyridamole